3% SPL7013 Gel (VivaGel)

DRUG2 trials

Sponsors

Starpharma Pty Ltd

Conditions

HIV InfectionsHSV-2 Genital HerpesHealthy

Phase 1

Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

CompletedNCT00442910

Starpharma Pty LtdHealthy

Start: 2007-07-31End: 2009-12-31Updated: 2010-06-24

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

CompletedNCT00740584

Starpharma Pty LtdHIV Infections, HSV-2 Genital Herpes

Start: 2008-08-31End: 2009-03-31Updated: 2018-10-30

Related Papers

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

2011-09-1597 citations